This is an investigational study. Ruxolitinib is FDA approved and commercially available for the treatment of patients with intermediate or high-risk myelofibrosis. Decitabine is FDA approved and commercially available for the treatment of patients with several different types of myeloid diseases such as myelodysplastic syndromes (MDS). It is investigational to give these drugs in combination with each other to patients with AML.